Camptothecins in Cancer Therapy (eBook)

Val R. Adams (Herausgeber)

eBook Download: PDF

2007 | 2005
XIII, 460 Seiten
Humana Press (Verlag)
978-1-59259-866-3 (ISBN)

Infos

A critical review our current understanding of camptothecins, their shortcomings, and of the possibilities for improving their clinical performance. The authors discuss new camptothecin analog development, drug delivery issues for optimizing their anticancer activity, and their potential use in a variety of different cancers. Additional chapters describe what is known about the biochemistry, the pharmacology, and the chemistry of the camptothecins, including the mechanism of topoisomerase and how camptothecins poison this enzyme, the use of animal models in defining the anticancer potential of camptothecins, and the question of camptothecin resistance.

Inhalt

Part I: Biochemistry, Pharmacology, and Chemistry

Mechanism of Action of Topoisomerase 1 Poisons
Leroy F. Liu and Shyamal D. Desai

Crystallographic Insight Into the Mechanism of Drug-Induced Topoisomerase I DNA Damage
Alex B. Burgin, Jr., Michael D. Feese, Bart L. Staker, and Lance Stewart

Inhibitors of Topoisomerase I Function
Sidney M. Hecht

Cytotoxic Mechanisms of the Topoisomerase 1 Inhibitors
Yves G. Pommier, Juana Barceló, Takahisa Furuta, Haruyuki Takemura, Olivier Sordet, and ZhiYong Liao

Biochemical and Genetic Analyses of DNA Topoisomerase 1-Mediated DNA Damage
Robert C. A. M. van Waardenburg and Mary-Ann Bjornsti

Preclinical Models for Evaluating Topoisomerase I-Targeted Drugs
Aarti S. Juvekar, Joyce Thompson, Clinton F. Stewart, and Peter J. Houghton

Mechanisms of Resistance to Camptothecins
Zeshaan A. Rasheed and Eric H. Rubin

Recent Advances in Camptothecin Drug Design and Delivery Strategies
Thomas G. Burke, Tian-Xiang Xiang, Bradley D. Anderson, and Lori J. Latus

Part II: Clinical Perspectives

Clinical Experience With 9-Aminocamptothecin: Lessons for New Drug Development
Chris H. Takimoto

Clinical Studies of Rubitecan (9-Nitro 20(S) Camptothecin)
Hilary Hewes, Judith A. Smith, and Claire Verschraegen

Irinotecan: Current Clinical Status and Pharmacological Aspects
Laurent P. Rivory

Clinical Experience With Topotecan
Aimee K. Bence and Val R. Adams

The Clinical Development of Lurtotecan: Experience With Water-Soluble and Liposomal Forms
Keith T. Flaherty, James P. Stevenson, Christopher J. Twelves, and Peter J. O'Dwyer

Preclinical and Clinical Development of Exatecan (DX-8951f): A Hexacyclic Camptothecin Analog
Eric K. Rowinsky

Camptothecins in the Treatment of Primary Brain Tumors
Clinton F. Stewart,Markos Leggas, and Henry S. Friedman

Camptothecins in the Treatment of Lung Cancer
Pankaj Kumar, Missak Haigentz, Jr., Jorge Gomez, and Roman Perez-Soler

Use of Camptothecins in the Treatment of Leukemia and Related Disorders
Benjamin M. F. Mow and Scott H. Kaufmann

Index

Produkt-Details

• Erscheint lt. Verlag: 27.10.2007
• Reihe/Serie: Cancer Drug Discovery and Development
• Reihe/Serie: Cancer Drug Discovery and Development
• Zusatzinfo: XIII, 460 p.
• Verlagsort: Totowa
• Sprache: englisch
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Chirurgie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Onkologie
• Themenwelt: Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie
• Schlagworte: biochemistry • brain • Brain Tumors • Cancer • Cancer Therapy • Chemistry • DNA • Drug • Drug Delivery • drug design • leukemia • pharmacology • Poison • Research • resistance
• ISBN-10: 1-59259-866-8 / 1592598668
• ISBN-13: 978-1-59259-866-3 / 9781592598663